de Geode Capital Management Catalyst Pharmaceutical CPRX Historial de posiciones en acciones
Compró
Mantenido
Vendió
| Trimestre | Valor de mercado | Estado | Núm. de acciones |
Cambio en la participación | Valor operado | Peso en el portafolio | Posición de la cartera | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q3 | – | Vender |
-3,150,256
| Cerradas | -USD 99 M | – | 4414 |
|
|
2026
Q2 | USD 99 M | Comprar |
3,150,256
+177,854
| +6% | +USD 5.25 M | 0.01% | 1215 |
|
|
2026
Q1 | USD 73.6 M | Comprar |
2,972,402
+72,065
| +2% | +USD 1.72 M | ﹤0.01% | 1271 |
|
|
2025
Q4 | USD 67.7 M | Comprar |
2,900,337
+10,017
| +0.3% | +USD 223 k | ﹤0.01% | 1314 |
|
|
2025
Q3 | USD 56.9 M | Comprar |
2,890,320
+23,637
| +0.8% | +USD 486 k | ﹤0.01% | 1392 |
|
|
2025
Q2 | USD 62.2 M | Comprar |
2,866,683
+101,127
| +4% | +USD 2.39 M | ﹤0.01% | 1313 |
|
|
2025
Q1 | USD 67.1 M | Comprar |
2,765,556
+100,084
| +4% | +USD 2.25 M | 0.01% | 1202 |
|
|
2024
Q4 | USD 55.6 M | Comprar |
2,665,472
+1,048
| +0% | +USD 22.5 k | ﹤0.01% | 1363 |
|
|
2024
Q3 | USD 53 M | Vender |
2,664,424
-34,189
| -1% | -USD 634 k | ﹤0.01% | 1391 |
|
|
2024
Q2 | USD 41.8 M | Comprar |
2,698,613
+190,461
| +8% | +USD 2.97 M | ﹤0.01% | 1471 |
|
|
2024
Q1 | USD 40 M | Comprar |
2,508,152
+307,927
| +14% | +USD 4.64 M | ﹤0.01% | 1509 |
|
|
2023
Q4 | USD 37 M | Comprar |
2,200,225
+113,858
| +5% | +USD 1.56 M | ﹤0.01% | 1524 |
|
|
2023
Q3 | USD 24.4 M | Comprar |
2,086,367
+159,952
| +8% | +USD 2.14 M | ﹤0.01% | 1699 |
|
|
2023
Q2 | USD 25.9 M | Comprar |
1,926,415
+72,193
| +4% | +USD 1.04 M | ﹤0.01% | 1682 |
|
|
2023
Q1 | USD 30.7 M | Comprar |
1,854,222
+90,832
| +5% | +USD 1.5 M | ﹤0.01% | 1517 |
|
|
2022
Q4 | USD 32.8 M | Comprar |
1,763,390
+76,269
| +5% | +USD 1.17 M | ﹤0.01% | 1441 |
|
|
2022
Q3 | USD 21.6 M | Vender |
1,687,121
-4,671
| -0.3% | -USD 55.4 k | ﹤0.01% | 1669 |
|
|
2022
Q2 | USD 11.9 M | Vender |
1,691,792
-62,178
| -4% | -USD 456 k | ﹤0.01% | 2135 |
|
|
2022
Q1 | USD 14.5 M | Comprar |
1,753,970
+23,657
| +1% | +USD 167 k | ﹤0.01% | 2099 |
|
|
2021
Q4 | USD 11.7 M | Vender |
1,730,313
-166,663
| -9% | -USD 1.1 M | ﹤0.01% | 2343 |
|
|
2021
Q3 | USD 10.1 M | Comprar |
1,896,976
+32,343
| +2% | +USD 177 k | ﹤0.01% | 2454 |
|
|
2021
Q2 | USD 10.7 M | Comprar |
1,864,633
+97,768
| +6% | +USD 505 k | ﹤0.01% | 2410 |
|
|
2021
Q1 | USD 8.14 M | Comprar |
1,766,865
+164,171
| +10% | +USD 652 k | ﹤0.01% | 2499 |
|
|
2020
Q4 | USD 5.35 M | Comprar |
1,602,694
+54,666
| +4% | +USD 184 k | ﹤0.01% | 2568 |
|
|
2020
Q3 | USD 4.6 M | Vender |
1,548,028
-26,464
| -2% | -USD 103 k | ﹤0.01% | 2437 |
|
|
2020
Q2 | USD 7.27 M | Comprar |
1,574,492
+33,135
| +2% | +USD 149 k | ﹤0.01% | 2115 |
|
|
2020
Q1 | USD 5.93 M | Comprar |
1,541,357
+37,036
| +2% | +USD 152 k | ﹤0.01% | 2041 |
|
|
2019
Q4 | USD 5.64 M | Vender |
1,504,321
-19,083
| -1% | -USD 89.2 k | ﹤0.01% | 2380 |
|
|
2019
Q3 | USD 8.09 M | Comprar |
1,523,404
+119,613
| +9% | +USD 637 k | ﹤0.01% | 2073 |
|
|
2019
Q2 | USD 5.39 M | Comprar |
1,403,791
+257,369
| +22% | +USD 1.11 M | ﹤0.01% | 2332 |
|
|
2019
Q1 | USD 5.85 M | Comprar |
1,146,422
+82,654
| +8% | +USD 243 k | ﹤0.01% | 2238 |
|
|
2018
Q4 | USD 2.04 M | Comprar |
1,063,768
+101,584
| +11% | +USD 291 k | ﹤0.01% | 2761 |
|
|
2018
Q3 | USD 3.64 M | Comprar |
962,184
+1,616
| +0.2% | +USD 5.06 k | ﹤0.01% | 2569 |
|
|
2018
Q2 | USD 3 M | Comprar |
960,568
+104,720
| +12% | +USD 318 k | ﹤0.01% | 2614 |
|
|
2018
Q1 | USD 2.04 M | Comprar |
855,848
+109,837
| +15% | +USD 365 k | ﹤0.01% | 2745 |
|
|
2017
Q4 | USD 2.92 M | Comprar |
746,011
+118,799
| +19% | +USD 392 k | ﹤0.01% | 2537 |
|
|
2017
Q3 | USD 1.58 M | Comprar |
627,212
+13,363
| +2% | +USD 36.7 k | ﹤0.01% | 2874 |
|
|
2017
Q2 | USD 1.69 M | Comprar |
613,849
+151,172
| +33% | +USD 316 k | ﹤0.01% | 2825 |
|
|
2017
Q1 | USD 902 k | Comprar |
462,677
+1,446
| +0.3% | +USD 1.84 k | ﹤0.01% | 3066 |
|
|
2016
Q4 | USD 484 k | Comprar |
461,231
+964
| +0.2% | +USD 1.1 k | ﹤0.01% | 3276 |
|
|
2016
Q3 | USD 501 k | Comprar |
460,267
+241
| +0.1% | +USD 217 | ﹤0.01% | 3246 |
|
|
2016
Q2 | USD 326 k | Vender |
460,026
-19,961
| -4% | -USD 16.1 k | ﹤0.01% | 3396 |
|
|
2016
Q1 | USD 561 k | Comprar |
479,987
+4,314
| +0.9% | +USD 6.69 k | ﹤0.01% | 3163 |
|
|
2015
Q4 | USD 1.16 M | Comprar |
475,673
+5,601
| +1% | +USD 16 k | ﹤0.01% | 2821 |
|
|
2015
Q3 | USD 1.41 M | Comprar |
470,072
+62,085
| +15% | +USD 268 k | ﹤0.01% | 2666 |
|
|
2015
Q2 | USD 1.68 M | Comprar |
407,987
+55,139
| +16% | +USD 220 k | ﹤0.01% | 2607 |
|
|
2015
Q1 | USD 1.53 M | Comprar |
352,848
+87,104
| +33% | +USD 314 k | ﹤0.01% | 2607 |
|
|
2014
Q4 | USD 789 k | Vender |
265,744
-16,590
| -6% | -USD 45.5 k | ﹤0.01% | 2973 |
|
|
2014
Q3 | USD 937 k | Vender |
282,334
-14,926
| -5% | -USD 39 k | ﹤0.01% | 2812 |
|
|
2014
Q2 | USD 751 k | Comprar |
297,260
+123,472
| +71% | +USD 264 k | ﹤0.01% | 2971 |
|
|
2014
Q1 | USD 392 k | Comprar |
173,788
+8,370
| +5% | +USD 17.5 k | ﹤0.01% | 3250 |
|
|
2013
Q4 | USD 322 k | Mantener |
165,418
| – | – | ﹤0.01% | 3258 |
|
|
2013
Q3 | USD 505 k | Mantener |
165,418
| – | – | ﹤0.01% | 2942 |
|
|
2013
Q2 | USD 147 k | Comprar |
+165,418
| Nuevas | +USD 132 k | ﹤0.01% | 3331 |
|
Otros fondos que tienen CPRX en su cartera
Posición de Geode Capital Management en CPRX: resumen de T3 2026
Geode Capital Management cerró por completo su posición en Catalyst Pharmaceutical (CPRX) en T3 2026, liquidando una posición de 3,150,256 acciones por un valor estimado de USD 99 M.
Geode Capital Management reportó por primera vez una posición en CPRX en T2 2013 y la mantuvo durante 53 trimestres. La posición alcanzó su máximo de USD 99 M en T2 2026. Al cierre de T3 2026, 2 fondos que sigue Wall St. Rank mantienen una posición en CPRX.
- Geode Capital Management reportó que ya no tenía una posición en Catalyst Pharmaceutical al cierre de T3 2026, después de venderla por completo durante el trimestre.
- Geode Capital Management vendió 3,150,256 acciones de Catalyst Pharmaceutical en T3 2026, por un valor estimado de USD 99 M.
- Geode Capital Management reportó por primera vez una posición en Catalyst Pharmaceutical en T2 2013 y la mantuvo durante 53 trimestres.
- La posición de Geode Capital Management en Catalyst Pharmaceutical alcanzó su máximo de USD 99 M en T2 2026.
- Al cierre de T3 2026, 2 fondos que sigue Wall St. Rank tenían Catalyst Pharmaceutical en cartera.
Según el Informe 13F de Geode Capital Management correspondiente a T3 2026, presentado el 6 nov 2026.